Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | INCAGN01876 + Retifanlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCAGN01876 | INCAGN1876|INCAGN-1876|INCAGN 1876 | GITR Antibody 6 | INCAGN01876 is an activating monoclonal antibody that binds to the glucocorticoid-induced tumor necrosis factor receptor, TNFRSF18 (GITR, CD357), which leads to activation of GITR and potentially results in activation of anti-tumor immunity (NCI Drug Dictionary). | |
Retifanlimab | MGA 012|INCMGA00012|MGA012 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 86 | Retifanlimab (INCMGA00012) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04225039 | Phase II | INCAGN01876 + Retifanlimab | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |